Search Results

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.

Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives.

Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology Annual Meeting on June 2, 2024 in Chicago, Illinois.

Fulgent Genetics, Inc. today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024.

Fulgent Genetics, Inc. today announced financial results for its fourth quarter and full year ended December 31, 2023.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results before the market opens on Friday, November 3, 2023.